The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Open accessAbstract
Protein kinases are a large family of approximately 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction. The clinical success of a number of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large number of kinases may represent therapeutically relevant targets. To date, the majority of clinical and preclinical kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases. Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket. Irreversible kinase inhibitors have a number of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacological specificity through mutation of the reactive cysteine residue. Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biological activity profiles. In addition, we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Thompson, J. D., Higgins, D. G., & Gibson, T. J. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4673 · Cited by 64,617
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Self-citationA quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Transforming gene product of Rous sarcoma virus phosphorylates tyrosine
Hunter, T., & Sefton, B. M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1311 · Cited by 2,332
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192 · cited 1×
“This mutation is believed to induce resistance by decreasing the Km for ATP thereby increasing the concentration of inhibitor needed to efficiently inhibit signaling (Yun et al., 2007).”
The origins of protein phosphorylation
Cohen, P. (2002) · Nature Cell Biology · doi:10.1038/ncb0502-e127 · Cited by 1,139
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Self-citationNovel mutant-selective EGFR kinase inhibitors against EGFR T790M
Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013
Self-citationEvolution of protein kinase signaling from yeast to man
Manning, G., Plowman, G. D., Hunter, T., & Sudarsanam, S. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02179-5 · Cited by 979
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Halogen atoms in the modern medicinal chemistry: hints for the drug design
Hernandes, M., Cavalcanti, S. M., Moreira, D. R., de Azevedo Junior, W., & Leite, A. C. (2010) · Current Drug Targets · doi:10.2174/138945010790711996 · Cited by 723
Chemical Modification of Proteins at Cysteine: Opportunities in Chemistry and Biology
Chalker, J. M., Bernardes, G. J. L., Lin, Y. A., & Davis, B. G. (2009) · Chemistry – An Asian Journal · doi:10.1002/asia.200800427 · Cited by 649
Kwok, B. H. B., Koh, B., Ndubuisi, M. I., Elofsson, M., & Crews, C. M. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00049-7 · Cited by 515
Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors
Cohen, M. S., Zhang, C., Shokat, K. M., & Taunton, J. (2005) · Science · doi:10.1126/science1108367 · Cited by 506
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., & Taunton, J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.925 · Cited by 493
Functional Interrogation of the Kinome Using Nucleotide Acyl Phosphates
Patricelli, M. P., Szardenings, A. K., Liyanage, M., Nomanbhoy, T. K., Wu, M., Weissig, H., Aban, A., Chun, D., Tanner, S., & Kozarich, J. W. (2007) · Biochemistry · doi:10.1021/bi062142x · Cited by 418
Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12022 · Cited by 418
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
Discovery of Potent and Selective Covalent Inhibitors of JNK
Zhang, T., Inesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S. B., Machleidt, T., Xie, T., Marto, J. A., Kim, N., Sim, T., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.11.010 · Cited by 349
Self-citationIn Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases
Patricelli, M. P., Nomanbhoy, T. K., Wu, J., Brown, H., Zhou, D., Zhang, J., Jagannathan, S., Aban, A., Okerberg, E., Herring, C., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.04.011 · Cited by 348
Self-citationCovalent Modifiers: An Orthogonal Approach to Drug Design
Potashman, M. H., & Duggan, M. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8008597 · Cited by 346
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Barf, T., & Kaptein, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003203 · Cited by 331
Lee, J.-H., Koo, T. H., Yoon, H., Jung, H. S., Jin, H. Z., Lee, K., Hong, Y.-S., & Lee, J. J. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.08.014 · Cited by 308
Tsou, H.-R., Overbeek-Klumpers, E. G., Hallett, W. A., Reich, M. F., Floyd, M. B., Johnson, B. D., Michalak, R. S., Nilakantan, R., Discafani, C., Golas, J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040159c · Cited by 301
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
Cowan-Jacob, S. W., Fendrich, G., Floersheimer, A., Furet, P., Liebetanz, J., Rummel, G., Rheinberger, P., Centeleghe, M., Fabbro, D., & Manley, P. W. (2007) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906047287 · Cited by 296
Conformational selection or induced fit? 50 years of debate resolved
Changeux, J.-P., & Edelstein, S. (2011) · F1000 Biology Reports · doi:10.3410/b3-19 · Cited by 271
Smaill, J. B., Rewcastle, G. W., Loo, J. A., Greis, K. D., Chan, O. H., Reyner, E. L., Lipka, E., Showalter, H. D. H., Vincent, P. W., Elliott, W. L., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990482t · Cited by 269
Idiosyncratic Drug Reactions: Past, Present, and Future
Uetrecht, J. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700186p · Cited by 257
Chemistry and biology of resorcylic acid lactones
Winssinger, N., & Barluenga, S. (2007) · Chem. Commun. · doi:10.1039/b610344h · Cited by 255
Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., & Okazaki, O. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027797 · Cited by 251
Underwood, D. C., Osborn, R. R., Kotzer, C. J., Adams, J. L., Lee, J. C., Webb, E. F., Carpenter, D. C., Bochnowicz, S., Thomas, H. C., Hay, D. W. P., et al. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39230-4 · Cited by 241
Haber, D. A., Gray, N. S., & Baselga, J. (2011) · Cell · doi:10.1016/j.cell.2011.03.026 · Cited by 214
Self-citationSmith, A. J. T., Zhang, X., Leach, A. G., & Houk, K. N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800498e · Cited by 193
Leproult, E., Barluenga, S., Moras, D., Wurtz, J.-M., & Winssinger, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101396q · Cited by 193
Targeted covalent drugs of the kinase family
Singh, J., Petter, R. C., & Kluge, A. F. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.168 · Cited by 177
The Development of HKI‐272 and Related Compounds for the Treatment of Cancer
Wissner, A., & Mansour, T. S. (2008) · Archiv der Pharmazie · doi:10.1002/ardp.200800009 · Cited by 174
Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides
Schirmer, A., Kennedy, J., Murli, S., Reid, R., & Santi, D. V. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600445103 · Cited by 169
A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
Zhou, W., Hur, W., McDermott, U., Dutt, A., Xian, W., Ficarro, S. B., Zhang, J., Sharma, S. V., Brugge, J. S., Meyerson, M. M., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.02.007 · Cited by 135
Self-citationHigh-resolution functional proteomics by active-site peptide profiling
Okerberg, E. S., Wu, J., Zhang, B., Samii, B., Blackford, K., Winn, D. T., Shreder, K. R., Burbaum, J. J., & Patricelli, M. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501205102 · Cited by 110
Singh, J., Dobrusin, E. M., Fry, D. W., Haske, T., Whitty, A., & McNamara, D. J. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960380s · Cited by 108
Liu, Q., Kirubakaran, S., Hur, W., Niepel, M., Westover, K. D., Thoreen, C. C., Wang, J., Ni, J., Patricelli, M. P., Vogel, K. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.304485 · Cited by 108
Self-citationIrreversible Nek2 Kinase Inhibitors with Cellular Activity
Henise, J., & Taunton, J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200222m · Cited by 96
Jacob, C., Battaglia, E., Burkholz, T., Peng, D., Bagrel, D., & Montenarh, M. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200342b · Cited by 96
Bansal, R., Magge, S., & Winkler, S. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10773 · Cited by 92
Role of a cysteine residue in the active site of ERK and the MAPKK family
Ohori, M., Kinoshita, T., Yoshimura, S., Warizaya, M., Nakajima, H., & Miyake, H. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.12.083 · Cited by 85
Development and Applications of a Broad-Coverage, TR-FRET-Based Kinase Binding Assay Platform
Lebakken, C. S., Riddle, S. M., Singh, U. P., Frazee, W. J., Eliason, H. C., Gao, Y. Q., Reichling, L. J., Marks, B. D., & Vogel, K. W. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109339207 · Cited by 82
Yoshimura, N., Kudoh, S., Kimura, T., Mitsuoka, S., Matsuura, K., Hirata, K., Matsui, K., Negoro, S., Nakagawa, K., & Fukuoka, M. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.10.006 · Cited by 81
Wissner, A., Fraser, H. L., Ingalls, C. L., Dushin, R. G., Floyd, M. B., Cheung, K., Nittoli, T., Ravi, M., Tan, X., & Loganzo, F. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.03.055 · Cited by 76
Zapf, C. W., Gerstenberger, B. S., Li, X., Limburg, D. C., Anderson, D. R., Caspers, N. L., Han, S., AULABAUGH, A. E., Kurumbail, R. G., Shakya, S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301190s · Cited by 76
Irreversible Protein Kinase Inhibitors
Garuti, L., Roberti, M., & Bottegoni, G. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796391705 · Cited by 76
PFAAT version 2.0: A tool for editing, annotating, and analyzing multiple sequence alignments
Caffrey, D. R., Dana, P. H., Mathur, V., Ocano, M., Hong, E., Wang, Y. E., Somaroo, S. S., Caffrey, B. E., Potluri, S., & Huang, E. S. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-381 · Cited by 66
Jogireddy, R., Dakas, P., Valot, G., Barluenga, S., & Winssinger, N. (2009) · Chemistry - A European Journal · doi:10.1002/chem.200901375 · Cited by 60
Wissner, A., Floyd, M. B., Johnson, B. D., Fraser, H. L., Ingalls, C. L., Nittoli, T., Dushin, R. G., Discafani, C. M., Nilakantan, R., Marini, J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050559f · Cited by 59
Kinase inhibitors in the treatment of immune-mediated disease
Kontzias, A., Laurence, A. D. J., Gadina, M., & O’Shea, J. J. (2012) · F1000 Medicine Reports · doi:10.3410/m4-5 · Cited by 59
Pérez, D. I., Conde, S., Pérez, C., Gil, C., Simón, D., Wandosell, F. G., Moreno, F. J., Gelpí, J. L., Luque, F. J., & Martínez, A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.08.042 · Cited by 58
Natural products as kinase inhibitors
Liu, J., Hu, Y., Waller, D. L., Wang, J., & Liu, Q. (2012) · Natural Product Reports · doi:10.1039/c2np00097k · Cited by 58
Self-citationGoto, M., Chow, J. C., Muramoto, K., Chiba, K., Yamamoto, S., Fujita, M., Obaishi, H., Tai, K., Mizui, Y., Tanaka, I., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.156554 · Cited by 55
Redox‐Based Probes for Protein Tyrosine Phosphatases
Leonard, S. E., García, F., Goodsell, D. S., & Carroll, K. S. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201007871 · Cited by 54
Binding of Manumycin A Inhibits IκB Kinase β Activity
Bernier, M., Kwon, Y.-K., Pandey, S., Zhu, T., Zhao, R., Maciuk, A., He, H., de Cabo, R., & Kole, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511878200 · Cited by 46
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase
Hur, W., Velentza, A. V., Kim, S., Flatauer, L. J., Jiang, X., Valente, D., Mason, D. E., Suzuki, M., Larson, B., Zhang, J., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.062 · Cited by 41
Self-citation17-Acetoxyjolkinolide B irreversibly inhibits IκB kinase and induces apoptosis of tumor cells
Yan, S., Li, Y., Wang, Y., Shen, S., Gu, Y. J., Wang, H., Qin, G.-W., & Yu, Q. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0263 · Cited by 40
In Vivo Efficacy of Natural Product‐Inspired Irreversible Kinase Inhibitors
Barluenga, S., Jogireddy, R., Koripelly, G. K., & Winssinger, N. (2010) · ChemBioChem · doi:10.1002/cbic.201000205 · Cited by 34
Muramoto, K., Goto, M., Inoue, Y., Ishii, N., Chiba, K., Kuboi, Y., Omae, T., Wang, Y. J., Gusovsky, F., & Shirota, H. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.168583 · Cited by 19
Sonoda, H., Omi, K., Hojo, K., Nishida, K., Ōmura, S., & Sugita, K. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00259-3 · Cited by 12
Cited by
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Proteome-wide covalent ligand discovery in native biological systems
Backus, K. M., Correia, B. E., Lum, K. M., Forli, S., Horning, B. D., González-Páez, G. E., Chatterjee, S., Lanning, B. R., Teijaro, J. R., Olson, A. J., et al. (2016) · Nature · doi:10.1038/nature18002 · Cited by 940
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Self-citation
Metadata
- Authors
- Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S.
- Venue
- Chemistry & Biology
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 20
- Issue
- 2
- Pages
- 146-159
- ISSN
- 1074-5521 (ISSN-L)
- OpenAlex
- W2167854315
- Cited by
- 652
- References
- 74
- FWCI
- 21.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.